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CARDIOLOGY

Challenges of Managing Giant Cell Myocarditis: A
Case Report on the Mechanical Support Perspective
Abdul W Kazi, MD, MBA1, Harsh Doshi, MD2
1. Division of Hospital Medicine, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
2. Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

INTRODUCTION
Giant cell myocarditis is a rare and fatal disease which
may result in heart failure, complete heart block, or
ventricular arrhythmias. We describe a patient who
previously had been discharged from our institution
with a left ventricular assist device and immunosuppressive therapy for management of his giant cell
myocarditis. His subsequent course was complicated
by further deterioration of heart function which required
multiple mechanical circulatory support devices. He
successfully received a heart transplant which later had
recurrence of giant cell myocarditis. This case highlights
the challenges of left and right sided mechanical assist
devices in managing giant cell myocarditis.

CASE PRESENTATION
AG is a 33-year-old Hispanic man with a history of heart
failure with reduced ejection fraction secondary to
giant cell myocarditis implanted with a HeartMate3 left
ventricular assist device (LVAD) who presented after
experiencing low flow alarms.
The patient presented with a three-week history of
diffuse abdominal pain and low-flow alarms on his
LVAD. Device parameters were as follows: flow of 3.3 L/
min, speed of 5500 rpm, PI of 4.2, and Power of 3.9
Watts. Echocardiography was significant for right
ventricular dilation and hypertrophy and severely
decreased right ventricular function. CT abdomen/
pelvis showed hepatic venous congestion and a
thick-walled descending colon. There were new findings
of fluid overload with new pleural effusions, ascites, and
anasarca. The patient was admitted due to worsening
right heart failure and increasing inotrope requirements.
He also tested positive for SARS COV-2 on admission
PCR testing despite being asymptomatic and afebrile.
Right heart catheterization showed RA pressure of
25mmHg, RV 30/25 mmHg, PA 30/25/28, PCWP
25mmgHg with a CO of 2.7, CI of 1.5, SVR of 2516, and
PVR of 1.1. The patient was started on milrinone for
inotropic support. He also began workup for right

23 52022
6 | The
Published
by Medicine
JeffersonForum,
DigitalVolume
Commons,

ventricular assist device as a bridge to heart transplantation and received a CT angiogram which showed
scarring of R IJ from a prior Protek Duo temporarily
placed on a previous admission. This resulted in
unfavorable subclavian anatomy for a new Protek Duo.
Due to concern for worsening RV dysfunction, RHC
was repeated five days later which showed RA
27mmHg, PA 34/23, PCWP 23 with CI of 1.57, CO of
2.87, PVR of 1.04, and SVR of 2033. Milrinone dose was
increased and dobutamine was added. The patient
continued to clinically deteriorate so an Impella RP
was placed One day after placement of the device, AG
had darkening of his urine, elevated LDH, and decreased
hemoglobin and platelet count, consistent with deviceinduced hemolysis. A subsequent right IJ angioplasty
was performed to allow for placement of a Protek
Duo. The patients undocumented immigration status
had in the past resulted in limited opportunities for
transplantation, however acquisition of health
insurance since then allowed for the patient to be a
candidate for an orthotropic heart transplant.

DISCUSSION & KEY POINTS
Giant cell myocarditis (GCM) is a rare and fatal disease
resulting in significant mortality due to heart failure,
complete heart block, and ventricular arrhythmias.
Patients with GCM often present at middle-age in
fulminant heart failure or arrythmias, and early diagnosis
is critical for management. Even for patients diagnosed
with GCM during their lifetimes and managed with
immunosuppressive therapy, transplant-free survival at
5-years is only 48%1. While the pathophysiology of GCM
is not entirely understood, it is characterized by
T-lymphocyte myocardial inflammation that can be
diagnosed on gold-standard endomyocardial biopsy2.
Diffuse myocardial inflammatory infiltrates with multinucleated giant cells can also be targeted for biopsy with
cardiac MRI assistance. Imaging findings are consistent
with myocardial fibrosis; there is myocardial strain and
late-gadolinium enhancement visible at affected areas
of the myocardium3.
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Immunosuppression of T-mediated inflammation with
prednisone, azathioprine, and cyclosporine can mitigate
the disease and improve survival. Patients should also
be optimized with goal directed medical therapy for
heart failure, but unstable hemodynamic presentation
can limit the extent of medical management. Despite
immunosuppression and medical management,
mortality is high and serious ventricular tachycardias
continue to be the single most prominent reason for
death in patients with GCM4. Immunosuppression and
ICD placement are mainstays of GCM therapy, but this
report focuses on mechanical circulatory support
(MCS) devices and their role in GCM management.
There are a variety of options for MCS when managing
GCM. These options can be temporary or durable, but
destination therapy is limited to orthotopic heart
transplant. The decision for types of MCS can be
influenced by the patient's clinical status, degree of
cardiac dysfunction, institutional preferences, and
patient’s listing status for transplant. Because of the rare
and fulminant presentation of GCM, it is common for
patients to be severely symptomatic prior to
biopsy-proven diagnosis. In one case series of seven
GCM patients the time interval from referral to device
placement or transplant ranged from 2 days to 4
months, and GCM was not diagnosed in any patient
prior to intervention5. There is favorable evidence for
VA-ECMO as the first temporary MCS option 6 . In
addition to ECMO, intra-aortic balloon pumps (IABP) or
other trademarked devices are feasible as temporary
bridge-therapy. More durable MCS options include
LVAD, BiVAD, or total artificial heart (TAH) implants.
In the case of AG, the patient had a previous admission
with right ventricular dysfunction requiring a Protek
Duo RVAD. The Protek Duo Cannula has been shown
to be a safe and effective option for short term
Bi-Ventricular support in conjunction with a secondary
LV device7. This is a dual lumen cannula device percutaneously inserted via the internal jugular vein and
positioned to have the inflow lumen in the right atrium
and the outflow lumen positioned in the main
pulmonary artery. A disadvantage of short-term
percutaneous RV assist devices is the possibility of
venous scarring resulting in difficulty of device
re-insertion. For AG, venous angioplasty was a safe and
effective technique to allow for Protek Duo re-insertion
in a patient with unfavorable anatomy who has failed
Impella RP placement.

GCM recurrence after transplant despite continuing
immunosuppressive therapy8. The rarity, severity, and
acuity of giant cell myocarditis results in limited ability to
conduct randomized control trials. Despite these
barriers to establishing better evidence-based
management, the use of MCS, and immunosuppressive
therapy are still cornerstones of therapy as bridgetherapy to cardiac transplantation.
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After hemodynamic stabilization, AG was able to
successfully receive an OHT. His clinical course was
then complicated by recurrence of GCM. Studies have
shown that approximately 12% of patients can have
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